NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results
--Advanced NGM282 into Phase 2b ALPINE 2/3 clinical study in NASH-- --Received $177.8 million in aggregate net proceeds in April from Initial Public Offering and private placement with Merck-- SOUTH SAN FRANCISCO, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- …